Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T E Delea

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Current Oncology (Toronto, Ont.)|August 19, 2016
Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in CanadaJ Amdahl, J Diaz, J Park, et al.
British Journal of Cancer|September 1, 2012
Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinomaT E Delea, A Khuu, D Y C Heng, et al.
The American Journal of Medicine|September 1, 1989
Cimetidine and adverse reactions: a meta-analysis of randomized clinical trials of short-term therapyJ M Richter, G A Colditz, D M Huse, et al.
Journal of the National Medical Association|October 1, 1987
Cost effectiveness of labetalol and propranolol in the treatment of hypertension among blacksG Oster, D M Huse, T E Delea, et al.
The American Journal of Cardiology|April 6, 1999
Cost effectiveness of carvedilol for heart failureT E Delea, M Vera-Llonch, R E Richner, et al.
Medical Care|May 1, 1996
The benefits and risks of over-the-counter availability of nicotine polacrilex ("nicotine gum")G Oster, T E Delea, D M Huse, et al.
Medical Care|September 1, 1990
The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockersG Oster, D M Huse, T E Delea, et al.
Current Oncology (Toronto, Ont.)|January 10, 2013
Cost-effectiveness of zoledronic acid compared with clodronate in multiple myelomaT E Delea, K El Ouagari, J Rotter, et al.
Current Oncology (Toronto, Ont.)|December 10, 2014
Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in CanadaT E Delea, J Amdahl, H R Nakhaipour, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Current Oncology (Toronto, Ont.)|August 19, 2016
Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in CanadaJ Amdahl, J Diaz, J Park, et al.
British Journal of Cancer|September 1, 2012
Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinomaT E Delea, A Khuu, D Y C Heng, et al.
The American Journal of Medicine|September 1, 1989
Cimetidine and adverse reactions: a meta-analysis of randomized clinical trials of short-term therapyJ M Richter, G A Colditz, D M Huse, et al.
Journal of the National Medical Association|October 1, 1987
Cost effectiveness of labetalol and propranolol in the treatment of hypertension among blacksG Oster, D M Huse, T E Delea, et al.
The American Journal of Cardiology|April 6, 1999
Cost effectiveness of carvedilol for heart failureT E Delea, M Vera-Llonch, R E Richner, et al.
Medical Care|May 1, 1996
The benefits and risks of over-the-counter availability of nicotine polacrilex ("nicotine gum")G Oster, T E Delea, D M Huse, et al.
Medical Care|September 1, 1990
The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockersG Oster, D M Huse, T E Delea, et al.
Current Oncology (Toronto, Ont.)|January 10, 2013
Cost-effectiveness of zoledronic acid compared with clodronate in multiple myelomaT E Delea, K El Ouagari, J Rotter, et al.
Current Oncology (Toronto, Ont.)|December 10, 2014
Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in CanadaT E Delea, J Amdahl, H R Nakhaipour, et al.
Pageof 2